Monica H. Vetter, MD

Articles by Monica H. Vetter, MD

Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer

January 20th 2025

Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts